Against notice was appetite stimulants Therapeutics and combines two drugs - naltrexone and bupropion. Bupropion is used to treat depression and addiction to smoking, while naltrexone is already in the treatment of addiction of opium withdrawal.
"Contrave is designed to activate a hypothalmic center in the brain associated with reduced appetite, while blocking beta-endorphin, which may be responsible for limiting weight loss. We are also studying the effects of Contrave on related central pathways associated with the rewarding nature of select high calorie foods."
Contrave is a fixed dose combination of Bupropion SR (sustained release) and tasty new formulation of naltrexone SR in a single tri-layer tablet. Raves container is designed to act on neurons in the brain with the aim of achieving appetite suppression, decreased food thirst, weight loss and sustainable.
Contrave raves in the three arms, the average decrease of visceral fat ranged from 13.7% to 16.7% after 24 weeks of treatment compared to an average reduction of 4.6% between the placebo group. In addition, the effect of Cont raves was significantly higher than that observed with one of the raves Cont individual components when administered alone. Visceral fat is located inside the abdominal cavity and around vital organs like the liver. Visceral fat accumulation, as opposed to subcutaneous fat that lies just below the skin is associated with an increased risk of cardiovascular disease and type II diabetes.
Showing posts with label health. Show all posts
Showing posts with label health. Show all posts
Tuesday, July 21, 2009
late-stage trials of Contrave experimental
Orexigen Therapy Inc. (OREX.O)said, the process of Contrave experimental weight loss drug rave step 3,almost meet their target and rise up nearly 25% of their shares.
Headquartered in San Diego and as a result of the plan to get U.S. regulatory approval in the first half of next year, the clinical criteria of significant weight loss Food and Drug Administration.
"These numbers are a drug is approved, the commercial sense," analyst Corey Davis contact details Bleichroeder Natixis said in a research note.
Orexigen said 48 percent of obese patients on a higher dose of Contrave lost at least 5 percent of their body weight, compared with 16.4 percent of those given a placebo in one trial. The same dose in another trial showed that 56.3 percent of patients achieved at least 5 percent weight loss vs. 17.1 percent of the placebo group.
"We are efficient 3 times better, said Orexigen CEO, Mike Narachi.
Contrave is a pill for antidepressant Wellbutrin, bupropion is a well-known, pending the release of naltrexone, OPIOIDOBUROKKA used to treat addiction and alcoholism.
Narachi Orexigen reason, the "quality" time for the NDA to the FDA next year has decided not to contact the rave for approval.
About 3,800 patients involved of 1 years trials.
Lower dose, weight at least 39.5 percent of patients rave 5% lose contact. Orexigen is developing three of the second dose, in order to improve the effectiveness of the test, that's not the best.
Is a weight-loss drugs, FDA guidelines, and 5% difference in body weight or placebo at the time of drug testing.
The main test of a single dose, patients, average weight loss 6.1%, placebo 1.3% - 4.8% points. In both tests was 5.2% points.
January 2007, contact Orexigen rave in absolute weight difference was 4.2 percent, announced the final results of the first stage of the experiment.
Headquartered in San Diego and as a result of the plan to get U.S. regulatory approval in the first half of next year, the clinical criteria of significant weight loss Food and Drug Administration.
"These numbers are a drug is approved, the commercial sense," analyst Corey Davis contact details Bleichroeder Natixis said in a research note.
Orexigen said 48 percent of obese patients on a higher dose of Contrave lost at least 5 percent of their body weight, compared with 16.4 percent of those given a placebo in one trial. The same dose in another trial showed that 56.3 percent of patients achieved at least 5 percent weight loss vs. 17.1 percent of the placebo group.
"We are efficient 3 times better, said Orexigen CEO, Mike Narachi.
Contrave is a pill for antidepressant Wellbutrin, bupropion is a well-known, pending the release of naltrexone, OPIOIDOBUROKKA used to treat addiction and alcoholism.
Narachi Orexigen reason, the "quality" time for the NDA to the FDA next year has decided not to contact the rave for approval.
About 3,800 patients involved of 1 years trials.
Lower dose, weight at least 39.5 percent of patients rave 5% lose contact. Orexigen is developing three of the second dose, in order to improve the effectiveness of the test, that's not the best.
Is a weight-loss drugs, FDA guidelines, and 5% difference in body weight or placebo at the time of drug testing.
The main test of a single dose, patients, average weight loss 6.1%, placebo 1.3% - 4.8% points. In both tests was 5.2% points.
January 2007, contact Orexigen rave in absolute weight difference was 4.2 percent, announced the final results of the first stage of the experiment.
Subscribe to:
Posts (Atom)
